Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Capital Expenditures (2020 - 2025)

Foghorn Therapeutics has reported Capital Expenditures over the past 6 years, most recently at $50000.0 for Q3 2025.

  • Quarterly results put Capital Expenditures at $50000.0 for Q3 2025, down 70.76% from a year ago — trailing twelve months through Dec 2025 was $50000.0 (down 94.48% YoY), and the annual figure for FY2025 was $50000.0, down 94.48%.
  • Capital Expenditures for Q3 2025 was $50000.0 at Foghorn Therapeutics, up from -$28000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for FHTX hit a ceiling of $2.0 million in Q2 2021 and a floor of -$407000.0 in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $80000.0 (2021), compared with a mean of $234947.4.
  • Biggest five-year swings in Capital Expenditures: plummeted 276.96% in 2022 and later surged 2782.61% in 2024.
  • Foghorn Therapeutics' Capital Expenditures stood at $80000.0 in 2021, then tumbled by 155.0% to -$44000.0 in 2022, then surged by 47.73% to -$23000.0 in 2023, then surged by 2782.61% to $617000.0 in 2024, then tumbled by 91.9% to $50000.0 in 2025.
  • The last three reported values for Capital Expenditures were $50000.0 (Q3 2025), -$28000.0 (Q2 2025), and $28000.0 (Q1 2025) per Business Quant data.